VUF11207 fumarate|cas:1785665-61-3|西域试剂

VUF11207 fumarate,98.92%

产品编号：Bellancom-110318| CAS NO：1785665-61-3| 分子式：C₃₁H₃₉FN₂O₈| 分子量：586.65

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-110318	￥1000.00	杭州北京（现货）
Bellancom-110318	￥1700.00	杭州北京（现货）
Bellancom-110318	￥3500.00	杭州北京（现货）
Bellancom-110318	￥6000.00	杭州北京（现货）
Bellancom-110318	￥10000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

VUF11207 fumarate

产品介绍

VUF11207 fumarate 是一种 CXCR7 激动剂，能与 CXCR7 特异性结合。VUF11207 fumarate 可通过抑制 ERK 的磷酸化来减少 CXCL12 介导的破骨细胞生成和骨吸收。

生物活性

VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation.

体外研究

VUF11207 fumarate (0.17 nM; 5 days) inhibits RANKL‑ and TNF‑α‑induced osteoclastogenesis through CXCL12 inhibition in osteoclast precursor cells.
VUF11207 fumarate inhibits osteoclastogenesis by suppressing phosphorylation of erk.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Osteoclast precursor cells (RANKL‑ and TnF‑α‑induced)
Concentration:	0.17 nM (100 ng/mL)
Incubation Time:	5 days
Result:	Showed inhibitory effect on CXCL12.

体内研究
(In Vivo)

VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male c57Bl/6J wild‑type/WT mice (8‑10‑week‑old; 20‑25 g; LPS-induced)
Dosage:	100 µg/day
Administration:	Subcutaneous injection; single daily for 5 days
Result:	Significantly decreased the number of osteoclasts and suppressed Cathepsin K mRNA, ranKl and TnF‑α mRNA expression levels. Reduced the area of LPS-induced bone resorption.

体内研究

VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male c57Bl/6J wild‑type/WT mice (8‑10‑week‑old; 20‑25 g; LPS-induced)
Dosage:	100 µg/day
Administration:	Subcutaneous injection; single daily for 5 days
Result:	Significantly decreased the number of osteoclasts and suppressed Cathepsin K mRNA, ranKl and TnF‑α mRNA expression levels. Reduced the area of LPS-induced bone resorption.

体内研究

VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male c57Bl/6J wild‑type/WT mice (8‑10‑week‑old; 20‑25 g; LPS-induced)
Dosage:	100 µg/day
Administration:	Subcutaneous injection; single daily for 5 days
Result:	Significantly decreased the number of osteoclasts and suppressed Cathepsin K mRNA, ranKl and TnF‑α mRNA expression levels. Reduced the area of LPS-induced bone resorption.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (170.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7046 mL	8.5230 mL	17.0459 mL
5 mM	0.3409 mL	1.7046 mL	3.4092 mL
10 mM	0.1705 mL	0.8523 mL	1.7046 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.55 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。